Vanguard Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$334K Hold
122,893
– – ﹤0.01% 2310
2026
Q2
$461K Hold
122,893
– – ﹤0.01% 2215
2026
Q1
$578K Buy
+122,893
New +$624K ﹤0.01% 2029

Other funds holding CTMX

Vanguard Asset Management's CTMX Position: Q3 2026 in Review

Vanguard Asset Management held its CytomX Therapeutics (CTMX) position steady in Q3 2026 at 122,893 shares worth $334K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

Vanguard Asset Management first reported a position in CTMX in Q1 2026 and has held it in 3 quarters since. The position peaked at $578K in Q1 2026. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Vanguard Asset Management held 122,893 shares of CytomX Therapeutics worth $334K as of Q3 2026.
  • Vanguard Asset Management left its CytomX Therapeutics share count unchanged in Q3 2026.
  • CytomX Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #2310 holding.
  • Vanguard Asset Management first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's CytomX Therapeutics position peaked at $578K in Q1 2026.
  • 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.